Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells

International Journal of Cancer

Volumn 110, Issue 5, 2004, Pages 741-750

  Rubinstein, Daniel B ^a   Stortchevoi, Alexei ^a,g   Boosalis, Michael ^a   Ashfaq, Raheela ^b   Ghebrehiwet, Berhane ^c   Peerschke, Ellinor I B ^d   Calvo, Fabien ^e   Guillaume, Thierry ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Adenocarcinoma antigen; gC1q receptor; Human immunoglobulin combinatorial library; Hyaluronan binding protein; Phage display

Indexed keywords

CELL PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENTARY DNA; GC1Q RECEPTOR; GLOBULAR PROTEIN; HYALURONIC ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; MESSENGER RNA; PROTEIN P32; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; BREAST CARCINOMA; CELL CULTURE; CELL INTERACTION; CELL SURFACE; COLON CARCINOMA; COMPLEMENT SYSTEM; DNA LIBRARY; ENDOMETRIUM CARCINOMA; ESOPHAGUS CARCINOMA; GENE SEQUENCE; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; METASTASIS; PANCREAS CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN MOTIF; PROTEIN PURIFICATION; RECEPTOR BINDING; SEQUENCE HOMOLOGY; STOMACH CARCINOMA; THYROID CARCINOMA;

ADENOCARCINOMA; ANTIGENS, CD44; BASE SEQUENCE; BLOTTING, NORTHERN; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MEMBRANE; COMPLEMENT C1Q; DNA, COMPLEMENTARY; EPITOPES; GENE LIBRARY; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MITOCHONDRIAL PROTEINS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PEPTIDE LIBRARY; PROTEIN BINDING; RECEPTORS, COMPLEMENT; RNA, MESSENGER; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 2942514464     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20105     Document Type: Article

References (67)

1. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997;9:681-3.
2. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumour antigens: molecular definitions and implications. Mol Med Today 1997;3:342-9.
3. Somers VA, Brandwijk RJ, Joosten B, Moerkerk PT, Arends J-W, Menheere P, Pieterse WO, Claessen A, Scheper RJ, Hoogenboom HR, Hufton SE. A panel of candidate tumor antigens in colorectal cancer revealed by serological selection of a phage displayed cDNA expression library. J Immunol 2002;169:2772-80.
4. Taylor-Papadimitriou J, Finn OJ. Biology, biochemistry and immunology of carcinoma-associated mucins. Immunol Today 1997;18:105-7.
5. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is over expressed in human breast cancer. Cancer Res 1996;56:860-5.
6. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK, Wey K, Royston I, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
7. Cho SH, Sahin A, Hortobagyi GN, Hittelman WN, Dhingra K. Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 1994;54:6302-5.
8. Henningsson CM, Selvaraj S, MacLean GD, Suresh MR, Noujaim AA, Longenecker BM. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo. Cancer Immunol Immunother 1987;25:231-41.
9. Jäger D, Stockert E, Scanlan MJ, Gure AO, Jaeger E, Knut A, Old LJ, Chen YT. Cancer-testis antigens and INGI tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 1999;59:6197-204.
10. Jäger D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jaeger E, Knuth A, Old LJ, Chen YT. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001;61:2055-61.
11. Karunagaran D, Tzahar E, Beerli RR, Hen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64.
12. Brasseur F, Marchand M, Vanwijck R, Herin M, Lethé B, Chomez P, Boon T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 1992;52:839-41.
13. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce CM. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996;40:171-8.
14. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Dennis J, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
15. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of human antibody fragment directed against the tumor T cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci USA 2000;97:7969-74.
16. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000;21:371-8.
17. Hoogenboom HR, Lutgerink JT, Pelsers MM, Rousch MJ, Coote J, Van Neer N, De Bruine A, Van Nieuwenhoven FA, Glatz JF, Arends JW. Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur J Biochem 1999;260:774-84.
18. Coomber WJ, Ward RL. Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display. Clin Cancer Res 2001;7:2802-8.
19. Hufton SE, Moerkerk PT, Meulemans EV, deBruine A, Arends JW, Hoogenboom HR. Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands. J Immunol Methods 1999;231:39-48.
20. de Kruif J, Terstappen L, Boel E, Logtenberg T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA 1995;92:3938-42.
21. Tordsson J, Abrahmsen L, Kalland T, Ljung C, Ingvar C, Brodin T. Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections. J Immunol Methods 1997;210:11-23.
22. + Fabs generated against hematopoietic stem cells in HIV-derived combinatorial immunoglobulin library suggest antigen-selected autoantibodies. Mol Immunol 1998;35:955-64.
23. Rubinstein DB, Storchevoi A, Boosalis M, Ashfaq R, Guillaume T. Over-expression of DNA-binding protein B (DbpB) gene product in breast cancer as detected by in vitro generated combinatorial human immunoglobulin libraries. Cancer Res 2002;62:4985-91.
24. Lekkerkerker A, Logtenberg T. Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells. J Immunol Methods 1999;231:53-63.
25. Kupsch JM, Tidman NH, Kang NV, Truman H, Hamilton S, Patel N, Bishop JA, Leigh IM, Crowe JS. Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clin Cancer Res 1999;5:925-31.
26. Guan IE, Burgess WH, Robinson SL, Goodman EB, McTigue KJ, Tenner AJ. Phagocyte cell molecules that bind the collagen-like region of C1q. Involvement in the C1q-mediated enhancement of phagocytosis. J Biol Chem 1991;366:20345-55.
27. Klickstein LB, Barbashov SF, Lie T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 1997;7:345-55.
28. Malhotra R, Thiel S, Reid KBM, Sim RB. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990;172:955-67.
29. Ghebrehiwet B, Lu PD, Zhang W, Keilbaugh SA, Leigh LE, Eggleton P, Reid KB, Peerschke EIB. Evidence that the two C1q binding membrane proteins, gC1q-R and cC1q-R, associate to form a complex. J Immunol 1997;159:1429-36.
30. Ghebrehiwet B, Lim BL, Peerschke EI, Willis AC, Reid KB. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J Exp Med 1994;179:1809-21.
31. Ghebrehiwet B, Lim B-L, Kumar R, Feng X, Peerschke EI. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. Immunol Rev 2001;180:65-77.
32. Das S, Deb TB, Kumar R, Datta K. Multifunctional activities of human fibroblast 34-kDa hyaluronic acid-binding protein. Gene 1997;190:223-5.
33. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert JD, Gordan O, Tureci O, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-9.
34. Toole BP. Hyaluronan and its binding protein, the hyaladherins. Curr Opin Cell Biol 1990;2:839-44.
35. Lu PD, Galanakis D, Ghebrehiwet B, Peerschke EIB. The receptor for the globular heads of C1q, gC1q-R, bind to fibrinogen and impairs its polymerization. Clin Immunol Immunopathol 1999;90:360-7.
36. Joseph K, Ghebrehiwet B, Peerschke EIB, Reid KBM, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor which binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci USA 1996;93:8552-7.
37. Lim B-L, Preissner K, Ghebrehiwet B, Leigh LEA, Reid KBM. The binding protein for the globular "heads" of complement C1q, gC1q-R: functional expression and characterization as a novel vitronectin binding factor. J Biol Chem 1996;271:26739-44.
38. Nguyen T, Ghebrehiwet B, Peerschke EIB. Staphylococcus aureus protein A recognizes platelet gC1q-R/p33: a novel mechanism for staphylococcus interactions with platelets. Infect Immunol 2000;68:2061-8.
39. Storz P, Hausser A, Link G, Dedio J, Ghebrehiwet B, Pfizenmaier K, Johannes F-J. Protein kinase C μ is regulated by the multifunctional chaperon protein p32. J Biol Chem 2000;275:24601-7.
40. Braun L, Ghebrehiwet B, Cossart P. gC1q-R/p32, a C1q-binding protein, is a novel receptor for Listeria monocytogenes. EMBO J 2000;19:1458-66.
41. Peerschke EIB, Ghebrehiwet B. Human blood platelet C1q-R/p33. Immunol Rev 2001;180:56-64.
42. Lah M, Goldstraw A, White JF, Dolezal O, Malby R, Hudson PJ. Phage surface presentation and secretion of antibody fragments using an adaptable phagemid vector. Hum Antibodies Hybridomas 1994;5:48-56.
43. Barth S, Weidenmuller U, Tur MK, Schmidt MF, Engert A. Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of scfv preselected by phage display. J Mol Biol 2000;301:751-7.
44. Dirksen WP, Li X, Mayeda A, Krainer AR, Rottman FM. Mapping the SF2/ASF binding sites in the bovine growth hormone exonic splicing enhancer. J Biol Chem 2000;275:29170-7.
45. Deb TB, Datta K. Molecular cloning of human fibroblast hyaluronic acid-binding protein confirms its identity with P-32, a protein co-purified with splicing factor SF2. J Biol Chem 1996;271:2206-12.
46. Peterson K, Zhang W, Keilbaugh SA, Peerschke EIB, Ghebrehiwet B. The C1q binding membrane proteins cC1q-R and gC1q-R are released from activated cells: subcellular localization and immunochemical characterization. Clin Immunol Immunopathol 1997;84:17-26.
47. Ghebrehiwet B, Peerschke EIB. Structure and function of gC1q-R: a multiligand binding cellular protein. Immunobiology 1998;199:225-38.
48. Mathews DA, Russell WC. Adenovirus core protein V interacts with p32, a protein which is associated with both the mitochondria and the nucleus. J Gen Virol 1998;79:1677-85.
49. Wang Y, Finnan JE, Middeldorp JM, Hayward SA. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus. Virology 1997;236:18-29.
50. Yu L, Loewenstein PM, Zhang Z, Green M. In vitro interaction of the human immunodeficiency virus type I Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP. J Virol 1995;69:3017-23.
51. Kitttlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1q-R and hepatitis C virus core protein inhibits T lymphocyte proliferation. J Clin Invest 2000;106:1239-49.
52. Dedio J, Jahmen-Dechent W, Bachman M, Muller-Estel W. The multiligand-binding protein gC1q-R putative C1q receptor is a mitochondria protein. J Immunol 1998;160:3534-42.
53. Fischer-Lindahl KE, Hermel E, Loveland BE, Wang CR. Maternally transmitted antigen of mice: a model transplantation antigen. Annu Rev Immunol 1991;9:351-72.
54. Soltys BJ, Gupta RS. Mitochondrial-matrix proteins at unexpected locations: are they exported? Trends Biochem Sci 1999;24:174-7.
55. 18-adrenergic receptor with gC1q-R, a multifunctional protein. J Biol Chem 1999;274:2149-54.
56. Jianzahong J, Zhang Y, Krainer A, Xu R-M. Crystal structure of p32, a doughnut-shaped acidic mitochondrial matrix protein. Proc Natl Acad Sci USA 1999;96:3572-7.
57. Sims RB. Interactions of C1q and the collectins with the potential receptor calreticulin (cC1q-R/collectin receptor) and megalin. Immunobiology 1998;199:208-24.
58. Chen Y-T, Güre AO, Tsang S, Stockert E, Jäger E, Knuth A, Old LJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998;95:6919-23.
59. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104-6.
60. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
61. Jurianz K, Garcia-Schüler SH, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999;36:929-39.
62. Hakulinen J, Meri S. Complement-mediated killing of microtumors in vitro. Am J Pathol 1998;153:845-55.
63. Harris CL, Kans KS, Stevenson GT, Morgan BP. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin Exp Immunol 1997;107:364-71.
64. White TK, Zhu Q, Tanzer ML. Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem 1995;270:15926-9.
65. Solomon E, Ledbetter DH. Report of the Committee on the Genetic Constitution of Chromosome 17. Cytogenet Cell Genet 1991;58:686-97.
66. Herwald H, Dedio J, Kellner R, Loos M, Muller-Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem 1996;271:13040-7.
67. Colman RW, Schmaier AH. Contact system: a vascular modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood 1997;90:3819-33.